We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




RNA Sequencing Offers Greater Capacity for Recovery and Analysis of Molecules

By LabMedica International staff writers
Posted on 01 Jan 2019
A recent paper described a significant modification that enables Drop-seq single-cell RNA sequencing technology to recover and analyze a more diverse variety of molecules.

Drop-seq methodology involves encapsulating single cells with single barcoded beads in nanoliter-sized droplets. More...
The barcoded oligo bead library is constructed such that each bead has a unique DNA barcode sequence, but within a bead, the thousands of copies of oligo all contain an identical barcode sequence. The 3′ end of the oligo has a poly(dT) stretch that captures messenger RNA (mRNA) and primes reverse transcription. Once encapsulated, the cell is broken open and the mRNA is captured on the bead, resulting in single-cell transcriptomes attached to microparticles. The RNA is converted to DNA, amplified and sequenced. The major drawback to the technique is that it can only identify molecules of mRNA, which limits the potential scope of analyses.

Investigators at Cornell University (Ithaca, NY, USA) described in the December 17, 2018, online edition of the journal Nature Methods a modification to Drop-seq. Their DART-seq (droplet-assisted RNA targeting by single-cell sequencing) method was depicted as being a versatile technology that enabled multiplexed amplicon sequencing and transcriptome profiling in single cells. The modification was accomplished by enzymatically customizing the beads prior to performing conventional Drop-seq analysis, which allowed for the recovery and analysis of a greater variety of molecules.

The investigators applied DART-seq to simultaneously characterize the non-A-tailed transcripts of a segmented dsRNA virus and the transcriptome of the infected cell. In addition, they used DART-seq to simultaneously determine the natively paired, variable region heavy and light chain amplicons and the transcriptome of B-lymphocytes.

"Those technologies are very popular because they have lowered the cost of these types of analyses and sort of democratized them, made them very cheap and easy to do for many labs," said senior author Dr. Iwijin De Vlaminck, assistant professor in of biomedical engineering at Cornell University.

Related Links:
Cornell University


New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
New
Gold Member
Aspiration System
VACUSAFE
New
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
New
Multi-Chamber Washer-Disinfector
WD 390
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Plasma pTau217 testing can predict future amyloid accumulation and cognitive decline in cognitively healthy older adults (photo courtesy of Shutterstock)

Blood Test Predicts Alzheimer Disease Risk Before Imaging Changes and Symptoms

Alzheimer's disease often advances silently for years, making timely risk stratification difficult in routine practice. Current approaches to detect pathology can involve lumbar puncture or positron emission... Read more

Industry

view channel
Image: The GenoPredict assay from Predicta Biosciences is available to Tempus Life Sciences partners to support exploratory research and clinical development programs (photo courtesy of Shutterstock)

Partnership Expands Ultrasensitive WGS Assay for for Hematologic Malignancies and MRD Monitoring

Tempus AI and Predicta Biosciences announced the commercial expansion of a co-branded whole‑genome sequencing assay GenoPredicta, which is intended for comprehensive genomic characterization of hematologic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.